Endotherapy for Nonvariceal Upper Gastrointestinal Hemorrhage

Chhagan L. Birda¹  Antriksh Kumar¹  Jayanta Samanta¹

¹Department of Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh, India

Address for correspondence Jayanta Samanta, MD, DM, Department of Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh, Sector -12, Chandigarh 160012, India (e-mail: dj_samanta@yahoo.co.in).

Introduction

Nonvariceal upper gastrointestinal hemorrhage (NVUGIH) is a common GI emergency with an incidence of approximately 60 to 80/100,000 population.¹ Despite recent advances in endoscopic hemostatic modalities, the mortality rate is 2 to 10%.¹ Risk factors for dismal clinical presentation and refractory bleed are advanced age, comorbid illness, history of prior GI bleed, recent surgery, and concomitant use of antithrombotic medications. There are various scoring systems available that incorporate the aforementioned risk factors to triage these patients.²-⁴ Hemodynamic stabilization to maintain adequate tissue perfusion is the key for better patient outcomes.⁵ Endoscopic assessment and adequate...
intervention are the cornerstone for the management of such patients. Various endoscopic modalities are available and have varying efficacies. Conventional methods of endotherapy include thermal and mechanical methods that achieve hemostasis in majority of patients. Emerging data of the newer modalities, such as over the scope clips (OTSC), hemostatic powders, and monopolar hemostatic forceps suggest their effectiveness both as rescue therapy after failed conventional modalities, as well as primary therapy. The focus of this review is to discuss the basic management of NVUGIH, as well as to summarize the various endoscopic methods available for the management of NVUGIH, their technical aspects, indications, and overall efficacy (Fig. 1).

Epidemiology of Nonvariceal Upper Gastrointestinal Hemorrhage

The clinical profile of variceal and nonvariceal bleed is different. Patients with variceal bleed are usually middle aged (40–60 years), males, and have a history of significant alcohol intake. These patients also have a higher rebleed rate and mortality. Patients with NVUGIH, especially peptic ulcer-related bleed, are usually elderly with associated comorbidities and antecedent history of nonsteroidal anti-inflammatory drugs (NSAIDs), antiplatelet, or anticoagulants use. Epidemiological studies from India have reported a lower mean age and a history of smoking/alcohol use in the majority of cases of upper GI bleed. Compared with the West, history of NSAIDs, antihypertensive, antiplatelet, and anticoagulants use is significantly lower. In India, ruptured esophageal varices is the most common cause of upper gastrointestinal bleed (UGIB) in contrast to the developed countries where peptic ulcer disease (PUD) dominates.

In the last two decades, there has been significant advances in the endoscopic and radiological hemostatic techniques with widespread use of proton pump inhibitor (PPI). However, more patients with precomorbid conditions or with antiplatelet/anticoagulant use have complicated the management strategy. Various studies have addressed the impact of these changes on epidemiology and treatment outcomes. U.S. survey showed a 21% decline in the hospitalization rate for UGIB with 30% decline in admission rates for PUD. However, there was no change in the hospitalization rates for variceal bleed. All cause UGIB-related mortality showed a 28% decline for NVUGIH but not so for variceal bleed. The mean age, comorbidities, the use of NSAIDs, and antiplatelet have increased over last few decades.

Preendoscopy Management

Prognostic Scoring

A patient presenting with NVUGIH should be triaged after assessing the hemodynamic status of the patient. The commonly used scores are Glasgow Blatchford scale (GBS), Rockall’s score, and AIMS-65. GBS is calculated at the time of admission, and a score >1 warrants inpatient management. Higher score predicts poorer outcome. A systematic review reported that the predictive value of GBS was superior to Rockall’s and AIMS-65 scores for identifying low risk patients. In a large prospective study, GBS had the highest accuracy (area under the receiver operating characteristic curve AUROC = 0.86) for predicting need for hospital-based intervention and death.

Supplementary Table S1 (available in the online version) summarizes commonly used scoring systems for upper GI bleed.

Resuscitation

Initial medical management include fluid resuscitation using crystalloids to maintain adequate tissue perfusion. Restrictive blood transfusion strategy (target of 7–9 g/dL) is preferred in view of lower rebleed rate and mortality except in patients with cardiovascular comorbidities where restrictive transfusion might result in acute coronary events.

Management of Antiplatelet and Anticoagulants

The risk–benefit ratio for patients receiving antithrombotic agents (antiplatelet/anticoagulants) should be gauged for bleeding versus thrombotic risk, if these agents are stopped. Decision should be taken by a multidisciplinary team including internists, gastroenterologists, cardiologists, and hematologists as higher rates of adverse cardiovascular events and all-cause mortality have been reported in those who stopped antithrombotic agents. Various guidelines recommend to continue aspirin if started as monotherapy or in combination for secondary cardiovascular prevention.

Aspirin for primary cardiovascular prophylaxis should be stopped temporarily and if indicated can be resumed within 5 days. Platelet transfusion can be considered in patients with severe UGI bleed with thrombocytopenia. All the anticoagulants need to be stopped temporarily and can be resumed within 1 week of hemostasis and can be bridged with heparin in patients with high risk of thromboembolism. Reversal of anticoagulation using vitamin K, prothrombin complex concentrate (PCC), or fresh frozen plasma (FFP), and reversal agents for direct oral anticoagulants (DOAC) should be considered in case of hemodynamic instability. However, the increased risk of thromboembolism and delayed onset of action should be kept in mind if anticoagulant reversal is done.
Proton Pump Inhibitors and Other Medications
High-dose intravenous (IV) PPI (80-mg bolus followed by 8 mg/hour infusion or intermittent bolus PPI) before endoscopy is suggested to downstage stigmata of recent hemorrhage and thereby need for endotherapy. However, PPI have no effect on clinically relevant patient outcomes such as blood transfusion requirement, surgery, and 30-day mortality. In view of lack of significant impact on patient-related outcomes and increased cost, various guidelines have now revised recommendations for routine preendoscopy PPI. In 2018, the Asia-Pacific working group recommended against the indiscriminate use of preendoscopy IV PPIs in hemodynamically stable patients. Octreotide and antibiotics have no role in NVUGIH but should be started if there is suspicion of variceal bleed. Tranexamic acid is not indicated in management of upper GI bleed as recent multicenter randomized controlled trial (RCT) showed not only absence of reduction in mortality but also increased risk of thromboembolic events. Use of prokinetics like erythromycin and metoclopramide 30 to 120 minutes before endoscopy has been shown to facilitate better visualization and successful endotherapy.

Role of Nasogastric Tube and Endotracheal Intubation
Role of nasogastric (NG) tube in management of patients with GI bleed is controversial. NG tube insertion has no impact on clinical outcome. Moreover, patient discomfort and invasiveness further limit routine insertion. Routine endotracheal intubation for airway protection is not recommended in view of increased incidence of aspiration, pneumonia, hospital stay, and mortality but should be considered in patients with massive bleed, hemodynamic instability, and altered sensorium.

Endoscopic Management
In a patient of suspected upper GI bleed, endoscopy plays a key role in the decision-making for further management. It identifies and localizes the source of bleed, plan, and administer treatment and also helps to assess rebleed risk.

When to do?
The timing to perform UGI endoscopy (UGIE) in acute NVUGIH is classified as emergent (done in <6 hours), early (done within 24 hours) and delayed (done after 24 hours). Multiple studies including a recent RCT by Lau et al have tried to ascertain the optimum timing to perform UGIE in such patients. Majority of the available guidelines recommend an early endoscopy (<24 hours), except for those with GBS of 0 to 1, where elective endoscopy on an out-patient basis can be considered. However, the timing for patients with hemodynamic instability has not been considered in many of them. To address this issue, the recent AGA guidelines advocate urgent endoscopy (<12 hours) in patients with moderate-to-large volume hematemesis in-hospital bleed, and those with hemodynamic instability despite adequate resuscitation.

Early esophagogastroduodenoscopy (EGD) is associated with better outcomes in UGIB. Early EGD is associated with a decreased risk of hypovolemia, acute kidney injury, acute respiratory failure, significant reduction in mortality, hospital stay, and lower total hospital cost. A multicenter study from Europe has also reported shorter hospital stay when EGD is performed within 24 hours. Jeong et al reported significantly higher mortality and longer hospital stay if EGD was delayed for >24 hours.

Choice of Instrument
Therapeutic endoscopes (single or double channel) are preferred since they allow better suctioning of gastric contents or blood clots and passage of larger accessories. An assistance of water jet is preferred as it helps in better visualization of lesions and successful endotherapy administration. Distal attachment cap further enhances the visualization. Duodenoscope can be used to address lesions located in the posterior duodenal wall or second part of duodenum.

Scanning Endoscopy
A keen observation is prerequisite while performing endoscopy. Esophagus should be carefully inspected for lesions such as Mallory–Weiss tear as retching during endoscopy can itself lead to such kind of lesions and may cause a diagnostic dilemma. If blood or clots are present in the fundus, first examine distally for any source of bleed. For visualizing the fundus, change of patient position to the reverse Trendelenburg, supine or right lateral position can be tried. Suction of gastric contents using large bore suction channel or using clot busting tubing/6-mm channel, removal of clots using retrieval nets, gastric lavage using wide bore NG tubes, or administering prokinetics before endoscopy are useful strategies to clear fundal contents. Since identification of one lesion does not preclude occurrence of another concomitant lesion, UGIE should be religiously performed examining all the segments.

Endoscopic Classification
Forrest’s classification is widely used to stratify risk of recurrent bleed and need for endotherapy in patients with peptic ulcer and has been summarized with its rebleeding risks in Supplementary Table S2 (available in the online version). In a large RCT, Forrest’s IB is associated with significantly lower rebleeding risk compared with Forrest’s IA, IIA, and IIB. Based on these results, peptic ulcers are reclassified as high risk (Forrest’s IA, IIA, and IIB), intermediate risk (Forrest’s IB and IIC), and low risk (Forrest’s III). The choice of therapy also needs consideration for other factors such as site and size of ulcer, surrounding tissue, and presence of any visible vessel.

Methods of Endoscopic Hemostasis
The three major categories of endoscopic hemostatic techniques are injection therapy, thermal methods, and mechanical methods. Injection therapy is done using agents such as epinephrine, sclerosing agents (absolute alcohol, ethanolamine, and polidocanol), and tissue adhesives (fibrin, thrombin, and cyanoacrylate glue). Contact thermal methods include heater probe, monopolar or bipolar electrocautery, and hemostatic forceps. Noncontact thermal methods include argon plasma coagulation (APC). Mechanical methods
include various types of through the scope (TTS) hemoclips and cap-assisted devices (OVESCO & Padlock). Topical hemostatic agents are upcoming noncontact methods to manage tumor-related bleed or any other diffuse bleed.

Conventional Methods
The various conventional methods encompass injection therapy with epinephrine, through-the-scope (TTS) clips, and thermal methods such as heater probe, gold probe, and APC. Epinephrine injection in combination with either thermal or mechanical therapy is recommended to manage Forrest’s IA and IB ulcers.35 However, for these high-risk lesions, adequate hemostasis can be achieved with either mechanical or thermal therapy alone. Monotherapy with thermal or mechanical methods is usually recommended for Forrest’s IIA ulcers.25,26 Adherent clots, in cases of Forrest’s IIB ulcers, should be removed using polypectomy snare, after which the stigmata of underlying vessel will direct the choice of subsequent endotherapy. Forrest’s IIC and III lesions are associated with minimal rebleed risk and hence these patients can be discharged on oral PPI therapy alone.25,26

Injection Therapy
Technical Aspect
Endoscopic injection is performed using 19- to 25-gauge needles which consist of an outer sheath and an inner hollow-core needle. For safe passage through the working channel, needle should be retracted into the plastic sheath. At the site of bleeding, the needle is extended out of the sheath and the solution is injected into the mucosa. Injection epinephrine (1:10,000 or 1:20,000 with normal saline) is injected in 0.5 to 2 mL aliquots in and around ulcer base. The primary mechanism of injection therapy is local tamponade resulting from a volume effect, so higher injected volume results in better hemostasis. A minimum of 5 to 10 mL is required for tamponade effect, better results are obtained with 10 to 30 mL. Volume of >30 mL increases risk of complications/perforations and should be avoided. Diluted epinephrine also have a secondary effect due to local vasoconstriction. Sclerosing agents, such as ethanol, ethanolamine, and polidocanol, produce hemostasis by causing direct tissue injury and thrombosis. Tissue adhesives including thrombin, fibrin, and cyanoacrylate glues create a primary seal at the site of bleeding.

Efficacy
Monotherapy using adrenaline should never be used because of high risk of rebleed. Head-to-head comparison with thermal and mechanical therapy showed comparable efficacy but significantly higher rebleeding rate in case of injection therapy.42-44 Adrenaline stops bleeding transiently by causing vasoconstriction and local tamponade and allows better visualization and successful application of mechanical or thermal therapy afterward.45 However, some recent studies have shown that thermal or mechanical monotherapy is as good as combination therapy.46,47

Mechanical Methods
Conventional methods of mechanical therapy includes TTS hemoclips. Variety of hemoclips having different properties is available and is summarized in Supplementary Table S3 (available in the online version).48 Hemoclip is deployed directly onto a bleeding vessel and it sloughs off within days to weeks after placement. The choice of these hemoclips depends on ulcer-related parameters and characteristics of the hemoclip like tensile strength, rotatability, and others. For confined spaces, use of a smaller clip with precise open and close system are preferred while for therapies with scope in full retroflexion or using duodenoscope elevator, clips with 360-degree rotatability are preferred. Clips with higher compression force are better for fibrotic and large ulcers.49

Technical Aspects
The clip is extended out of sheath after insertion of the delivery catheter through the working channel. The clip and target should be kept close to endoscope. The clip is opened with plunger handle and then positioned over the target area in tangential or enface approach either by repositioning of endoscope or by rotation of the clip. The target area is then grasped between jaws of the clips and clip is applied using the device handle. Slight suction before deployment of clip enables maximum tissue capture.

Efficacy
Primary hemostasis rate is 80 to 90% and comparable to thermal therapy.46-50,51 Meta-analysis comparing injection, thermal, and mechanical therapies concluded similar efficacy of each modalities for primary hemostasis but higher rebleeding rate if injection monotherapy was used.42-44

Thermal Methods
Conventional thermal methods are divided into two types: contact and noncontact thermal devices. Contact thermal methods include heater probe, monopolar, or bipolar electrocautery. Noncontact thermal methods include APC. Supplementary Table S4 (available in the online version) summarizes the various available thermal therapeutic modalities.48

Technical Aspect
Contact thermal devices generate heat which results in edema, coagulation of tissue proteins, and vasoconstriction. Mechanical pressure is also applied on probe tip for local tamponade combined with coagulation, a process known as “coaptive coagulation.” At least 8 seconds of forceful contact time of probe should be allowed for adequate hemostasis. Endoscope should be held as close to the treatment site to ensure obliteration of culprit vessel. Generator settings for thermal therapy are as follows: for heater probe, 25 to 30 J/pulse, 4 to 5 pulse (total 100–150 J); and for bipolar/multipolar probes, 15 to 20 Watts. Area and depth of tissue injury is limited by decreased electrical conductivity as the target tissue desiccates.
ACO uses high frequency, monopolar alternating current resulting in coagulation of superficial tissue. The electrons flow through a stream of electrically activated ionized argon gas causing tissue desiccation at the surface. Electrosurgical unit generator settings for ACO include soft coagulation mode, 40 W energy, and gas flow of 1 to 2 L/minute. Optimum distance from the probe tip to the target tissue should be around 2 to 8 mm.

**Efficacy**

Head-to-head comparison between mechanical and thermal therapy shows variable results. However, majority of studies have reported their equivalent efficacy (Table 1). Hence, the choice of therapy depends on availability of hemostatic modality and discretion of the endoscopist. In cases where there is a difficult location for successful hemoclip deployment or the lesion has a surrounding fibrotic bed, thermal therapy can be preferentially considered. Similarly hemoclips can be preferred in anticoagulant-related bleeding lesions as they cause limited tissue injury.

**Newer Modalities**

Despite recent advances, the conventional methods fail to achieve hemostasis in 10 to 24% of NVUGIH cases. Ulcer size >2 cm, visible vessel >2 mm, location at posterior duodenal wall, or along lesser curvature, underlying gastrroduodenal or left gastric artery and fibrotic ulcer bed are predictors of failure for conventional methods. To overcome these limitations of conventional therapy, newer endoscopic modalities have been developed and studied in patients with NVUGIH. These newer modalities include over-the-scope clips, hemostatic forceps, hemostatic sprays, radiofrequency ablation, cryotherapy, endoscopic suturing devices, and endoscopic ultrasound (EUS) guided angiotherapy.

**Hemostatic Forceps (Coagrasper)**

**Technical Aspect**

Hemostatic forceps (HF) first gained popularity in its use for hemostasis during Per oral endoscopic myotomy (POEM) and endoscopic submucosal dissection (ESD). Antispip jaw further increases its efficacy. For ulcer bleed or bleeding vessel, HF can be applied, using soft coagulation, directly by contacting the bleeding point/vessel with the closed tip or by catching the vessel. The risk of perforation is extremely low because of using lower voltage and without any carbonization. Potential disadvantages of HF is a reduced coagulation effect in presence of blood, clots, or water between the tip of the forceps and the bleeding point. Additional patients with pacemakers and implantable cardioverter-defibrillators need to have their cardiac device mode adjusted.

**Efficacy**

One RCT comparing Coagrasper and heater probe reported primary hemostasis in 96% patients treated with Coagrasper compared with 67% in the other group. Another RCT reported higher initial success rate, lower rebleed rates, fewer adverse events, and shorter procedure time in patients receiving hemostasis using HF compared with patients managed with hemoclips (Table 2). Guidelines recommended hemostatic forceps as alternative treatment option of hemostasis in patients with ulcer-related bleed.

**Cap-Mounted Clips**

Cap-mounted clips (e.g., Over the Scope Clip [OTSC], OVESCO Endoscopy, Germany; and Padlock system, Steris Endoscopy) have been evaluated in treating NVUGIH as first line or salvage therapy (Table 2).

**Technical Aspects**

Cap-assisted devices utilize an applicator cap preloaded with a nitinol clip that fits onto the tip of the endoscope. In the OTSC system, the cap-mounted clip is affixed to the tip of the endoscope. A clip-release thread is retrogradely pulled through the working channel and is fixed onto a hand wheel. The clip is released by turning the hand wheel in a manner similar to deploying a variceal ligation band. The Padlock system is installed on the handle of the endoscope and connects to the clip by a linking cable delivery system on the outside of the endoscope. Padlock system deploys its clip using “Lock-it” releasing mechanism. Accurate positioning and adequate retraction of tissue into the cap of the device is required before the clip can be properly deployed. Due to its unique design and elastic properties of nitinol, cap-assisted devices close itself, and ensures therapeutic effects.

**Efficacy**

In a retrospective study (FLETROck study), OTSC was found to be effective as a first-line therapy in high-risk ulcer patients. Meta-analysis of 21 studies showed 97% efficacy of OTSC as first line therapy. A study comparing cap-assisted clips versus standard therapy as first line treatment of NVUGIH reported OTSC to be more effective, as well as safe. In a multicenter RCT (‘STING’ trial) of patients with recurrent bleed, OTSC was found to be more effective than conventional mechanical and thermal therapies. Based on these evidences, recent guidelines recommend cap-assisted clips as the first-line therapy in patients with high-risk ulcers and as a rescue therapy after failed conventional methods and in patients with recurrent bleed.

**Topical Hemostatic Powder**

Topical hemostatic powders (TC-325, Endoclot & UI-EWD) have been found to be effective in patients with bleeding related to tumor, ulcer, and those having diffuse ooze from the mucosal surface (Table 2).

**Technical Aspects**

C-325 or hemospray (Cook Medical) is an inorganic, absorbent powder which concentrates clotting factors at the bleeding site and forms a coagulum. The coagulum typically sloughs within 3 days and is naturally eliminated. Hemospray consists of a pressurized CO2 canister, a TTS delivery catheter, and a reservoir for the powder cartridge. Endoclot (Endoclot Plus, Santa Clara, California, United States) is a biocompatible starch-derived compound that rapidly absorbs water from serum and concentrates coagulation factors, platelets, and red blood cells at the bleeding site. Another hemostatic powder
<table>
<thead>
<tr>
<th>Studies (year)</th>
<th>Study design</th>
<th>Study participants</th>
<th>No. of patients</th>
<th>Injection therapy</th>
<th>Mechanical therapy</th>
<th>Thermal therapy</th>
<th>Observation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saltzman et al (2005)</td>
<td>Prospective</td>
<td>Forrest’s I and II Forrest’s I, n = 22, Forrest’s IIIA, n = 13, and Forrest’s IIIB, n = 12</td>
<td>47</td>
<td>21 patients (epinephrine along with MPEC)</td>
<td>26 (TTS hemoclips)</td>
<td>21 (MPECl + epinephrine)</td>
<td>Primary hemostasis, rebleed rate, need of blood transfusion, hospital stay, surgery, and mortality were comparable</td>
</tr>
<tr>
<td>Cipolletta et al (2001)</td>
<td>RCT</td>
<td>Patient with ulcer related bleed with SRH</td>
<td>113</td>
<td>–</td>
<td>56 (TTS hemoclips)</td>
<td>57 (heater probe)</td>
<td>Primary hemostasis, 30-day mortality, and emergency surgery were comparable. Recurrent bleed, need of blood transfusion, and hospital stay were lower in hemoclip group</td>
</tr>
<tr>
<td>Lin et al (2002)</td>
<td>RCT</td>
<td>Active bleeding ulcer and NBVV were included</td>
<td>80</td>
<td>–</td>
<td>40 (TTS hemoclips)</td>
<td>40 (heater probe)</td>
<td>Primary hemostasis was significantly better for heater probe especially for difficult to approach bleeding. Recurrent bleed, need of blood transfusion, and hospital stay, surgery, and mortality were comparable</td>
</tr>
<tr>
<td>Lin et al (2003)</td>
<td>RCT</td>
<td>Forrest’s I and II</td>
<td>93</td>
<td>47 (hypertonic saline–epinephrine injection along with heater probe)</td>
<td>46 (5 excluded d/t technical failure)</td>
<td>47 (heater probe + hypertonic saline-epinephrine injection)</td>
<td>Primary hemostasis, rebleed rate, need of blood transfusion, hospital stay, surgery, and mortality were comparable</td>
</tr>
<tr>
<td>Peng et al (2013)</td>
<td>Retrospective</td>
<td>Forrest’s I and II</td>
<td>194</td>
<td>–</td>
<td>84 (TTS hemoclips)</td>
<td>110 (intermediate dose APC)</td>
<td>Recurrent bleeding at 1 week and at 1 month, blood transfusion requirement, surgery, and mortality were comparable. Hospital stay was significantly shorter in APC group</td>
</tr>
<tr>
<td>Sung et al (2007)</td>
<td>Meta-analysis including 15 RCTs</td>
<td>1,156</td>
<td>359 injection alone</td>
<td>390 TTS clips alone, 242 clips + injection</td>
<td>165 thromboagulation with/without injection</td>
<td>Definitive hemostasis, need of surgery, and mortality were comparable between thermal and mechanical therapies. Higher rebleed rate, need of surgery but no difference in mortality if injection therapy alone was used</td>
<td></td>
</tr>
<tr>
<td>Marmo et al (2007)</td>
<td>Meta-analysis including 20 RCTs</td>
<td>Combination therapy vs. monotherapy</td>
<td>Total patients = 2,472. Dual therapy, n = 1,233 and monotherapy, n = 1,239</td>
<td>Injection + clips vs. injection alone, n = 362</td>
<td>Injection + thermal vs. injection alone, n = 376</td>
<td>Injection + thermal vs. clip monotherapy, n = 234</td>
<td>Injection + thermal vs. clip monotherapy, n = 425</td>
</tr>
</tbody>
</table>

(Continued)
available in India is hemoseal powder (Shaili Endoscopy, Gujarat, India) which is collagen powder.

The hemostatic powder is delivered via a spray catheter placed through the endoscope’s working channel. During hemospray use, caution is required to prevent catheter block. Moisture should be avoided coming into contact with the catheter by preflushing of the accessory channel with 60 mL of air and detachment of suctioning tubing prior to insertion. The deploying catheter should be kept 1- to 2-cm away from bleeding site. Caution is required when using elevator in duodenoscopes or in retroflexed position to avoid kinking.

### Efficacy

In a multicenter registry of patients with peptic ulcer bleed, topical hemostatic agents were found to be 86% effective for primary hemostasis with 12.7% rebleed rate. Another RCT compared hemostatic powder with mechanical therapy (TTS) and reported no difference in rebleed, need of surgery, and mortality risk in two groups. Advantages of hemostatic powders include ease of application, efficacy in diffuse bleed with poor visualization, and tumor-related bleed. Potential disadvantages include rebleed, limited efficacy in Forrest’s IA ulcers due to rapid wash away effect, and efficacy only in presence of active bleeding. Recent guidelines recommend topical hemostatic powder as a temporary measure of rescue after failed conventional treatment, recurrent bleed, diffuse bleed, and tumor-related bleed.

### Endoscopic Suturing

Endoscopic suturing device (Overstitch, Apollo Endo-surgery, United States) has been evaluated in patients with ulcer-related bleed, particularly large, and deep and fibrotic ulcers. Various case reports and case series have reported a high success rate, as well as safety of this modality, in patients with large ulcers. Endoscopic suturing is limited by high rebleeding rate (29–38%), need of double channel therapeutic endoscope, and expert endoscopic skills (Table 3). Endoscopic suturing is contraindicated in suspected malignant ulcers.

### Endoscopic Ultrasound–Guided Intervention

EUS-guided angiotherapy is a promising modality for bleeding lesions that are inaccessible or refractory to standard endoscopic techniques. Most common lesions treated by EUS angiotherapy include Dieulafoy’s lesions, pseudoaneurysm, and gastrointestinal stromal tumors. Hemostasis is achieved using coils, cyanoacrylate/fibrin glue, or sclerosing agents (absolute alcohol and polidocanol). EUS-guided angiotherapy has been mostly used as a rescue therapy after failed conventional modalities.

### Endoscopic Doppler Ultrasound Probe

Endoscopic Doppler probes (EDPs) are currently available to guide hemostasis in patients with high risk of rebleed. Two EDPs are available at present: (1) the VTI Endoscopic Doppler system (Vascular Technology Inc., Massachusetts, United States) and (2) endo-DOP system (GmbH, Singen, Germany). While the VTI uses a 1.5-mm diameter probe using 20 MHz, the endo-DOP uses a 1.8-mm diameter probe with 16 MHz. The probe is applied at the bleeding point to pick up Doppler signals corresponding to the presence and course of the underlying vessels. Postendotherapy disappearance of signals can hint at success of therapy. One comparative study reported lower recurrent bleeding, surgery, and bleeding-related mortality in patients who received EDP-guided hemostasis compared with patients who received conventional treatment. Another study reported significantly lower rebleed rate, surgery, and major complications in patients who received EDP-guided hemostasis.

### Table 3

<table>
<thead>
<tr>
<th>Studies (year)</th>
<th>Study design</th>
<th>Study participants</th>
<th>No. of patients</th>
<th>Injection therapy</th>
<th>Mechanical therapy</th>
<th>Thermal therapy</th>
<th>Observation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calvet et al (2004)</td>
<td>Meta-analysis including 16 RCTs</td>
<td>Forrest’s IA, IB, IIa, and IIb ulcer patients received injection epinephrine alone vs. epinephrine with second modality</td>
<td>1,673</td>
<td>11 studies compared injection epinephrine vs. epinephrine + second injection therapy</td>
<td>Two studies compared injection epinephrine + clips vs. injection epinephrine alone</td>
<td>Three studies compared injection epinephrine + thermal therapy vs. injection epinephrine alone</td>
<td>Adding a second method to injection epinephrine reduced recurrent bleed, surgery, and mortality. Beneficial effect of adding second modality achieved regardless of which second hemostatic modality was applied</td>
</tr>
<tr>
<td>Vergara et al (2014)</td>
<td>Meta-analysis including 19 RCTs</td>
<td>Forrest’s IA, IB, IIa, and IIb ulcer patients received injection epinephrine alone vs. epinephrine with second modality</td>
<td>2,033</td>
<td>12 studies compared injection epinephrine vs. epinephrine + second injection therapy</td>
<td>Four studies compared injection epinephrine + clips vs. injection epinephrine alone</td>
<td>Three studies compared injection epinephrine + thermal therapy vs. injection epinephrine alone</td>
<td>Combination therapy reduces persistent and recurrent bleeding rate and need of emergency surgery compared with injection epinephrine alone. Mortality and adverse events not significantly different in combination and epinephrine alone groups</td>
</tr>
</tbody>
</table>

Abbreviations: APC, argon plasma coagulation; MPEC, multipolar electrocoagulation; RCT, randomized controlled trial; TTS, through-the-scope clip; NBVV, non-bleeding visible vessel; SRH, stigmata of recent hemorrhage.
Table 2  Studies on newer hemostatic modalities

<table>
<thead>
<tr>
<th>Study (year)</th>
<th>Design of study</th>
<th>Study participants</th>
<th>No. of patients</th>
<th>Newer hemostatic modality</th>
<th>Conventional method</th>
<th>Observations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kim et al (2015)</td>
<td>Prospective RCT</td>
<td>Forrest’s IA, IB, and IIA</td>
<td>151</td>
<td>HFSC + injection epinephrine: n = 76</td>
<td>APC + injection epinephrine: n = 75</td>
<td>Primary hemostasis, recurrent bleed at 30 days, rate of adverse events, and mortality were comparable between HFSC and APC groups</td>
</tr>
<tr>
<td>Nunoue et al (2015)</td>
<td>RCT</td>
<td>Forrest’s IA, IB, IIA, and IIB</td>
<td>111</td>
<td>Monopolar HFSC (group S): n = 56</td>
<td>Heater probe: n = 55</td>
<td>Primary hemostasis was higher in soft coagulation group (96 vs. 67%, p &lt; 0.001). Recurrent bleed was lower in soft coagulation group (13 vs. 0%, p &lt; 0.01)</td>
</tr>
<tr>
<td>Arima et al (2010)</td>
<td>RCT</td>
<td>Forrest’s IA, IB, IIA, and IIB</td>
<td>96</td>
<td>Monopolar HFSC: n = 48</td>
<td>Hemoclips: n = 48</td>
<td>Primary hemostasis, recurrent bleed, surgery, and mortality comparable between both the groups. Time to achieve hemostasis was significantly shorter in soft coagulation group</td>
</tr>
<tr>
<td>Kataoka et al (2013)</td>
<td>Prospective</td>
<td>Forrest’s IA, IB, and IIA</td>
<td>50</td>
<td>Bipolar HFSC: n = 27</td>
<td>Hemoclips: n = 23</td>
<td>Primary hemostasis was better in hemostatic forces group (100 vs. 78.2%, p &lt; 0.05). Recurrent bleed and procedure time were not significantly different</td>
</tr>
<tr>
<td>Richter-Schrag et al (2016)</td>
<td>Retrospective</td>
<td>UGIB (n = 69), LGIB (n = 31). Forrest’s IA, IB, IIA, and IIB in case of ulcer bleed and spurring and oozing in case of other etiology of bleed were enrolled</td>
<td>100</td>
<td>OTSC as FLET or SLET after failed conventional method</td>
<td>–</td>
<td>Primary hemostasis and clinical success was 88 and 77% respectively. OTSC when used as SLET have significantly higher re-bleeding rate compared with FLET</td>
</tr>
<tr>
<td>Wedi et al (2018)</td>
<td>Retrospective</td>
<td>NVUGIB patients underwent OTSC as FLET were included</td>
<td>118</td>
<td>OTSC as FLET were included</td>
<td>–</td>
<td>Primary successful hemostasis was achieved in 92.4%. Compared with Rockall’s risk category prediction, OTSC reduced persistent, and recurrent bleed and rebleeding related mortality</td>
</tr>
<tr>
<td>Chandrasekar et al (2019)</td>
<td>Meta-analysis including 21 studies</td>
<td>Upper and lower GI bleeding patients treated with OTSC as first-line or second-line treatment were included</td>
<td>851</td>
<td>OTSC (OVESCO)</td>
<td>–</td>
<td>Definitive hemostasis was 87.8% after 8 weeks. Technical success, clinical success, and rebleeding rates after OTSC were 97.8, 96.6, and 10.3%, respectively. Rebleeding was higher when OTSC used as SLET compared with FLET (26 vs. 9%).</td>
</tr>
<tr>
<td>Gölder et al (2019)</td>
<td>Prospective</td>
<td>Forrest’s IA, IB, and IIA gastric and duodenal ulcers</td>
<td>100</td>
<td>OTSC (OVERSCO)</td>
<td>–</td>
<td>Successful hemostasis, recurrent bleed, and clinical success were comparable between primary and secondary OTSC (90.9 vs. 94.1, 16.7 vs. 21.9, and 75.8 vs. 73.5%, respectively)</td>
</tr>
<tr>
<td>Jensen et al (2020)</td>
<td>RCT</td>
<td>Severe NVUGIH Ulcers and Dieulafoy’s lesions, Major SRH or lesser stigmata with arterial flow underneath documented by Doppler probe were included</td>
<td>53</td>
<td>OTSC: n = 25</td>
<td>Standard treatment (hemoclips, MPEC): n = 28</td>
<td>Significant differences in OTSC versus Standard groups in rates of re-bleeding (4 vs. 28.6%; p = 0.017); severe complications (0 vs. 14.3%) and units of red cell transfusions (0.04 vs. 0.68)</td>
</tr>
</tbody>
</table>

(Continued)
<table>
<thead>
<tr>
<th>Study (year)</th>
<th>Design of study</th>
<th>Study participants</th>
<th>No. of patients</th>
<th>Newer hemostatic modality</th>
<th>Conventional method</th>
<th>Observations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Schmidt et al (2018)</td>
<td>RCT</td>
<td>Recurrent peptic ulcer bleeding after initial endoscopic hemostasis were included</td>
<td>66</td>
<td>OTSC: n = 33</td>
<td>Standard treatment: n = 33 (TTS clips n = 31, therapy: n = 2)</td>
<td>Further bleeding (persistent or recurrent bleeding within 7 days) was significantly lower in OTSC group (15.2 vs. 57.6%, $p = 0.001$). Surgery, TAE, mortality, hospital stay, complications, and transfusion requirement were not different in both the groups</td>
</tr>
<tr>
<td>Brandler et al (2018)</td>
<td>Retrospective</td>
<td>High-risk lesions (&gt;2 mm, situated in area of a major artery and/or a deep penetrating, excavated, fibrotic ulcer with high-risk stigmata, where a perforation could not be ruled out or thermal therapy would cause perforation, or those that could not be treated by standard endoscopy</td>
<td>67</td>
<td>OTSC as primary therapy: n = 49, rescue therapy: n = 18</td>
<td>81.3% success rate of OTSC at 30 days. CAD was independent predictors of rebleed</td>
<td></td>
</tr>
<tr>
<td>Haddara et al (2016)</td>
<td>Retrospective registry</td>
<td>Ulcers: n = 75, malignant lesions: n = 61, postendoscopy: n = 35, others: n = 31</td>
<td>202</td>
<td>Hemospray (TC-325) Primary hemostatic method: n = 94, salvage therapy: n = 108</td>
<td>Immediate hemostasis achieved in 96.5%. Recurrent bleeding at day 8 and day 30 were 26.7 and 33.5%. Rebleeding rate more if melena at presentation and when TC-325 used as salvage therapy; 26.7% patients required additional treatment</td>
<td></td>
</tr>
<tr>
<td>Chen et al (2015)</td>
<td>Retrospective study</td>
<td>Nonmalignant NVUGIH: n = 21, Upper GI tumors: n = 19, LGIB: n = 11, intraprocedural bleed: n = 16</td>
<td>67</td>
<td>Hemospray (TC-325)</td>
<td>Primary hemostasis achieved in 98.5% patients. Early rebleeding (within 72 hours) occurred in 9.5% patients. No serious adverse events reported</td>
<td></td>
</tr>
<tr>
<td>Prei et al (2016)</td>
<td>Prospective observational study</td>
<td>NVUGIB: n = 58, LGIB: n = 12</td>
<td>70</td>
<td>Hemostatic powder (Endoclot) Primary therapy: n = 56 Rescue therapy: n = 14</td>
<td>Overall treatment success rate was 83% with one week re-bleed rate of 11.4%. Endoclot was served as bridge to surgery in 10% patients</td>
<td></td>
</tr>
<tr>
<td>Park et al (2019)</td>
<td>Retrospective study</td>
<td>Postendoscopy bleeding: n = 46, peptic ulcer: n = 8 tumor n = 1, other etiology: n = 1</td>
<td>56</td>
<td>Hemostatic adhesive powder (UI-EWD)</td>
<td>Technical success 100%, immediate hemostasis 96.4%, rebleed at 30 days 3.7%, no adverse events</td>
<td></td>
</tr>
<tr>
<td>Alzoubaidi et al (2020)</td>
<td>Prospective study</td>
<td>Peptic ulcer: n = 167, malignancy: n = 50, postendoscopic therapy bleed: n = 49, other: n = 48</td>
<td>314</td>
<td>Hemospray (TC-325)</td>
<td>Initial hemostasis achieved in 89.5%, recurrent bleed in 10.3%. Similar hemostasis between Hemospray monotherapy (92.4%), combination therapy (88.7%), and rescue therapy (85.5%)</td>
<td></td>
</tr>
</tbody>
</table>
Methods have been summarized in Supplementary Table S5 (available in the online version) and a flowchart for the possible management algorithm have been outlined in Fig. 2.

Table 2  (Continued)

<table>
<thead>
<tr>
<th>Study (year)</th>
<th>Design of study</th>
<th>Study participants</th>
<th>No. of patients</th>
<th>Newer hemostatic modality</th>
<th>Conventional method</th>
<th>Observations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baracat et al (2020)</td>
<td>RCT</td>
<td>Peptic ulcer: n = 26, malignancy: n = 9, postendoscopic therapy bleed: n = 49, post sphincterotomy: n = 6, Mallory–Weiss tear: n = 4, Dieulafoy’s lesion: n = 2, other: n = 11</td>
<td>39</td>
<td>Hemospray (TC-325) + injection epinephrine: n = 19</td>
<td>Hemoclips + injection epinephrine: n = 20</td>
<td>Primary hemostasis, rebleed, emergency surgery, and mortality comparable between the groups. Additional procedure required at relook endoscopy in five patients in Hemospray group compared with none in Hemoclips group (p = 0.04)</td>
</tr>
<tr>
<td>Prasad et al (2018)</td>
<td>Prospective study</td>
<td>Peptic ulcer related bleed</td>
<td>18, Forrest’s IA = 2, IB = 16</td>
<td>Endoscopic collagen spray (hemoseal spray)</td>
<td>Hemostasis was achieved in all patients. No rebleed after 48 hours. No adverse drug reaction</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: APC, argon plasma coagulation; FLET, first-line endoscopic therapy; GI, gastrointestinal; HFSC, hemostatic forces with soft coagulation; LGIB, lower GI bleed; NVUGIH, nonvariceal upper GI bleed; MPEC, multipolar electrocoagulation; OTSC, over-the-scope clip; RCT, randomized controlled trial; SLET, second-line endoscopic therapy; SRH, stigmata of recent hemorrhage; TAE, transcatheter angiographic embolization; TTS, through-the-scope clip; UGIB, upper GI bleed; CAD coronary artery disease.

Table 3  Advantages and disadvantages of newer modalities

<table>
<thead>
<tr>
<th>Hemostatic modality</th>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>OTSC</td>
<td>• Advanced endoscopy skills not required&lt;br&gt;• Effective for ulcers &gt; 2 cm</td>
<td>• Difficult to apply on hard, fibrotic ulcers&lt;br&gt;• After identification of bleeding source, endoscope requires to be withdrawn and reinsertion after mounting of OTSC&lt;br&gt;• Cost</td>
</tr>
<tr>
<td>Endoscopic suturing</td>
<td>• Effective for large, hard, fibrotic ulcers</td>
<td>• Double-channel endoscope needed&lt;br&gt;• Expert endoscopic skills&lt;br&gt;• Cost</td>
</tr>
<tr>
<td>Coagrasper</td>
<td>• Safe and effective&lt;br&gt;• Lower risk of perforation</td>
<td>• Ineffective if submerge in water/large surface area&lt;br&gt;• Cost</td>
</tr>
<tr>
<td>Hemospray</td>
<td>• Easy, safe, effective&lt;br&gt;• Diffuse, poorly localized bleed&lt;br&gt;• Malignancy related bleed</td>
<td>• Temporary method&lt;br&gt;• If fail, other modalities cannot be used immediately&lt;br&gt;• Works only if active bleed</td>
</tr>
<tr>
<td>EUS-guided angiography</td>
<td>• Target under direct vision&lt;br&gt;• Can confirm hemostasis with Doppler probe</td>
<td>• Higher endoscopy skills needed&lt;br&gt;• Resource intensive&lt;br&gt;• Costly</td>
</tr>
</tbody>
</table>

Abbreviations: EUS, endoscopic ultrasound; OTSC, over-the-scope clip; CAD, coronary artery disease.

Persistent and Recurrent Bleed

1. Persistent bleeding is defined as ongoing bleed despite standard hemostatic modality at the index endoscopy. Newer more effective modalities, like cap-mounted clips or hemostatic powder or Coagrasper, should be used as rescue therapy. If bleeding is refractory to all endoscopic hemostatic modalities, then transcatheter angiographic embolization (TAE) or surgery should be considered. Comparative studies between TAE and surgery reported higher rebleeding rate in case of TAE but lower adverse events and mortality compared with surgery.

2. Recurrent bleeding is defined as recurrence of bleeding after successful hemostasis manifesting as ongoing hematemesis, persistent hemodynamic instability, recurrence of melena after initial resolution, and drop of hemoglobin >2 g/dL after initial stabilization. The predictors of recurrent bleeding include ulcers of >2-cm size, nonbleeding visible vessel >2 mm, ulcers located on posterior duodenal wall, and high on lesser curvature and persistent positive Doppler signals. Repeat endoscopy is recommended as 73% patients respond to a second endoscopic intervention. During second endoscopy, conventional methods or rescue therapy with cap-mounted clips, hemostatic powders/spray, or hemostatic forceps can be considered.

The STING trial showed that for rebleed, OTSC performed better than conventional methods. OTSC has a success rate of 81.3% at day-30 to control rebleed in patients with high risk of rebleed. Thus, cap-mounted clips can be considered as the first-line hemostatic measure in high-risk patients or with recurrent bleed. Various registries and case reports have shown approximately 95% success rate of topical hemostatic powders/spray when used as first line or salvage therapy for various causes of GI bleed. Soft coagulation,
using hemostatic forceps, on head-to-head comparison with contact thermal/TTS clips showed higher rates of primary hemostasis, as well as lesser recurrent bleeding, although data exist for recurrent bleeding. Modified cyanoacrylate (cyanoacrylate associated with methacryloxyolene) can be used as rescue therapy in patients with NVUGIH with high success rate (78%). In predicted high-risk ulcers, prophylactic TAE can reduce rebleed rate, though more robust data are needed. When the second endoscopic therapy fails, TAE or surgery should be considered.

3. Relook endoscopy: routine second-look endoscopy is not recommended, as it is cost ineffective. Second-look endoscopy is indicated if there are signs of recurrent bleed or if initial hemostasis was not satisfactory. Prophylactic TAE is not indicated after successful endoscopic hemostasis even in the presence of high-risk stigmata of rebleed, as it is not cost-effective. EDP-guided hemostasis, although have shown less rebleeding rates, is not yet recommended in view of lack of high quality data. If second endoscopy fails to achieve hemostasis, then TAE and surgery should be considered.
Postendoscopy Management

High dose IV PPI is recommended for initial 72 hours to prevent recurrent bleed if high-risk stigmata (Forrest’s class IA, IB, IIA, and IIB) is observed during endoscopy. In case of no high-risk stigmata (Forrest’s IIC and III), patient can be discharged on once daily PPI. If *Helicobacter pylori* is positive during index endoscopy, anti-*H. pylori* therapy based on local resistance pattern should be prescribed and eradication should be documented. If *H. pylori* is negative at index endoscopy, repeat testing at 4 weeks is warranted as sensitivity of detection of *H. pylori* decreases in the presence of bleed. Antiplatelets can be resumed within 3 to 5 days and anticoagulants can be resumed within 7 days, if indicated, after consultation with a cardiologist. DOAC can be considered in this context in view of its rapid onset of action and better safety profile. If *H. pylori* is negative and antithrombotics need to be continued, then cotherapy with PPI is indicated to prevent recurrent bleed.

Strategy for Resource Limited Countries

Studies from resource-limited countries, such as Tanzania and Nigeria, have shown that 50% of the patients with UGIB having severe anemia did not receive blood transfusion while one-third to one-fourth of the cases could not be offered endotherapy. These studies suggest that immediate resuscitation, restrictive transfusion strategy, and early EGD may be cost-effective options. Use of prognostic scoring systems can help exclude low-risk patients from unnecessary hospital admissions. Preemptive PPI use may be a cost-effective strategy to reduce endotherapy need. Endoscopic thermal and injection therapy are cost-effective conventional techniques. OTSC has been found to be a cost-effective strategy for recurrent bleed.

Conclusion

Management of patients presenting with NVUGIH encompasses a multidisciplinary team approach to triage and stabilize the patient on presentation to the hospital. Endoscopy should be performed within 12 to 24 hours of presentation. Multiple modalities, both conventional and newer modalities, are available and a combination of these techniques can be used to optimize endotherapy. Persistent and recurrent bleed can be tackled using newer modalities. The various modalities have their specific techniques, advantages and efficacy levels and are to be used in accordance to the availability of the technique, expertise, and the patient and lesion-related factors to get the best outcome.

Authors’ Contributions

C.L.B.: conception and design, review of literature, data analysis, drafting the work, and final approval.

A.K.: review of literature, data analysis, drafting the work, and final approval.

J.S.: conception and design, data interpretation, intellectual review of the work, and final approval.

All the authors have approved the final version of the work.

Funding

None.

Conflict of Interest

None declared.

References

16. Ramaekers R, Mukarram M, Smith CA, Thiruganasambamothi V. The predictive value of preendoscopic risk scores to predict adverse outcomes in emergency
49 Wang Tj, Aihara H, Thompson AC, Schulman AR, Thompson CC, Ryou M. Choosing the right through-the-scope clip: a rigorous comparison of rotatability, whip, open/close precision, and closure strength (with videos). Gastrointest Endosc 2019;89(1):77–86.e1